Firm
The tie-up could result in the firm’s German and France-based teams, which both have strong UPC expertise, becoming independent
Price hikes at ‘big law’ firms are pushing some clients toward boutiques that offer predictable fees, specialised expertise, and a model built around prioritising IP
Koen Bijvank of Brinkhof and Johannes Heselberger of Bardehle Pagenberg discuss the Amgen v Sanofi case and why it will be cited frequently
King & Wood Mallesons will break into two entities, 14 years after a merger between a Chinese and an Australian firm created the combined outfit
Recently published Special Focus articles
Recently published Special Focus articles
-
Sponsored by Gün and PartnersSelin Sinem Erciyas of Gün + Partners suggests that intellectual property waivers and compulsory licensing are not the answer in developing and accessing vaccines, and explains why governments should be focused on R&D -
Sponsored by Wanhuida Intellectual PropertyYue Guan of Wanhuida Intellectual Property analyses a decision by the China National Intellectual Property Administration on the validity of a pulmonary hypertension drug and the implications for pharmaceutical patentees
-
Sponsored by Purplevine IPXiaoyan Zhou of Purplevine IP explains how the introduction of administrative measures for registering, and filing records relating to, medical devices in China should affect companies’ IP strategy
-
Sponsored by CASCAS explains the five high-risk areas of IP for R&D organisations and identifies how companies can protect their innovations and safeguard their growth potential
-
Sponsored by CASCAS shares how patent offices around the world are adopting AI, and explains the benefits of clean data, multiple algorithms, and leveraging human expertise alongside technology
-
Sponsored by CASThe CAS IP Research Team analyse how organisations are applying IP insights to accelerate scientific breakthroughs and identify potential risks to commercialisation
